ArticleJournal of inflammation research2025
Altered Iron Regulation and the Role of Ferritin Heavy Chain in Dermatomyositis Patients.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dermatomyositis (DM) is an acquired autoimmune disease, the underlying mechanism of which remains unclear. Systemic and myocellular iron homeostasis are deeply connected to inflammation, hypoxia, mitochondrial dysfunction, and different forms of cell death, which are involved in the pathogenesis of DM. This study aimed to investigate changes in key iron regulators transferrin receptor 1(TfR1), ferroportin (Fpn), ferritin heavy chain (FTH), and mitochondrial ferritin (FtMt) in DM and their possible roles. Methods: We included 11 patients with DM, 9 patients with disease controls, and 7 patients as normal controls. Systemically, ELISA was performed to measure the serum hepcidin levels. We used qRT-PCR and Western blotting to quantitatively analyze transferrin receptor 1(TfR1), ferroportin (Fpn), ferritin heavy chain (FTH), and mitochondrial ferritin (FtMt) in the muscle biopsy samples obtained from patients. Immunohistochemical staining and immunofluorescence were performed to determine protein expression. Results: Elevated serum hepcidin levels were observed in the patients with DM. In muscle tissues, the results showed increased mRNA levels of Conclusion: Iron regulators are altered in patients with DM, and the overexpression of FTH may contribute to the pathogenesis of perifascicular atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.